Embecta (NASDAQ:EMBC) Earns Buy Rating from BTIG Research

Embecta (NASDAQ:EMBC)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $25.00 price objective on the stock. BTIG Research’s target price indicates a potential upside of 138.78% from the stock’s current price.

EMBC has been the topic of a number of other research reports. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $18.50.

Embecta Price Performance

NASDAQ:EMBC opened at $10.47 on Friday. Embecta has a 12 month low of $9.20 and a 12 month high of $18.12. The firm has a market capitalization of $619.93 million, a PE ratio of 6.42 and a beta of 1.11. The business’s fifty day moving average price is $11.80 and its 200 day moving average price is $12.95.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company had revenue of $261.20 million for the quarter, compared to analysts’ expectations of $258.07 million. During the same quarter last year, the company earned $0.65 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities analysts anticipate that Embecta will post 2.85 EPS for the current year.

Institutional Trading of Embecta

A number of institutional investors have recently bought and sold shares of EMBC. Royal Bank of Canada raised its stake in shares of Embecta by 38.3% during the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after buying an additional 5,036 shares during the last quarter. AQR Capital Management LLC raised its position in Embecta by 3.7% during the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after acquiring an additional 8,109 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Embecta by 4.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock valued at $2,195,000 after purchasing an additional 7,894 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Embecta by 224.0% during the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after purchasing an additional 91,729 shares in the last quarter. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q1 beat on the bottom line — adjusted EPS $0.71 vs. consensus $0.67 and revenue of $261.2M topped estimates; management emphasized strategic progress in the quarter. Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Board declared a quarterly cash dividend of $0.15/share (annualized yield ~5.7%), with record/ex-dividend dates announced — supports income-focused shareholders. embecta Announces Quarterly Cash Dividend
• Positive Sentiment: Market reaction initially included modest upside as coverage noted the quarter beat Street estimates. Embecta stock ticks up on Street-beating Q1
• Neutral Sentiment: Earnings call transcript, highlights and slide deck are available for deeper read — investors can review management’s commentary on product mix, costs and commercialization cadence. Embecta Corp (EMBC) Q1 2026 Earnings Call Highlights

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.